← Association for Accessible Medicines
CMSRulemakingCMS-2017-0156

Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs For Contract Year 2019 CMS-4182-P

RIN
—
Last modified
Nov 25, 2025
Comment window
closed 3115d ago
Association for Accessible Medicines filings
1

Activity

Association for Accessible Medicines filed 1 comment on this docket between Jan 18, 2018 and Jan 18, 2018. 131 other organizations filed here. The comment window closed 3115d ago.

What Association for Accessible Medicines filed (1)

Jan 18, 2018· Association for Accessible Medicines-DC· CMS-2017-0156-1534

The Association for Accessible Medicines (AAM) appreciates the opportunity to provide input on the Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit, and the PACE Program proposed rule (CMS-4182-P). As manufacturers of nine out of every 10 prescription medicines dispensed in the United States, AAM members form an integral, and powerful, part of the healthcare system. Generic drugs have saved patients and the U.S. health care system $1.67 trillion in the last decade, generating $253 billion in savings in 2016 alone. Medicare savings amounted to $77 billion ($1,883 per enrollee) and Medicaid savings of $37.9 billion ($512 per enrollee). AAM is pleased with several of the proposals included in the rule, which we believe will help to strengthen the Part D prescription drug benefit for patients, and help make the benefit itself sustainable for the future. (Please see attached.)

View on regulations.gov →

Abstract

N/A

View on regulations.gov →

Co-filers (131)

See everyone who commented →